• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Video

Comparing Current Treatment Agents for AD

Author(s):

Christopher G. Bunick, MD, PhD,Ruth Ann Vleugels, MD, MPH, MBA

Experts discuss a recent network meta-analysis comparing current monotherapies for atopic dermatitis (AD) and how this may change standards of care.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older
December 16th 2024

ICYMI: FDA Approves Galderma's Nemolizumab for Moderate to Severe Atopic Dermatitis in Patients 12 and Older

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients
August 2nd 2024

The Cutaneous Connection: Intervening in AD Progression for Pediatric Patients

Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis
December 16th 2024

Arcutis Submits sNDA for Roflumilast Cream 0.05% to FDA for Patients Ages 2 to 5 with Atopic Dermatitis

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis
July 1st 2024

The Cutaneous Connection: Navigating Systemic Therapies in Atopic Dermatitis

Pediatric and Adult AD Cases Illuminate Benefits of Topical PDE4 Inhibitors
December 12th 2024

Pediatric and Adult AD Cases Illuminate Benefits of Topical PDE4 Inhibitors

A Family-Centered Approach to Managing AD
December 10th 2024

A Family-Centered Approach to Managing AD

© 2024 MJH Life Sciences

All rights reserved.